Abstract: A self-healing ceramic ion-selective membrane assembly including a ceramic ion-selective membrane, and at least one additive layer. The at least one additive layer includes an ionic ceramic material which is porous or ion-selective. The at least one additive layer having a metal cation diffusivity higher than the metal cation diffusivity of the ceramic ion-selective membrane. When a defect occurs through the ceramic ion-selective membrane, metal cation transport will be enhanced by orders of magnitude towards and into the defect, driven by the chemical or electrical potential difference between the two sides of the membrane.

Abstract: The present invention is directed to methods of preparing biocement. The methods disclosed herein employ microbial or enzymatic means first to generate acid which dissolves CaCO3, and then to degrade urea, producing CO3? ions which increase the pH and lead to the reprecipitation of CaCO3. The precipitation of CaCO3 acts as a cementation process which can bind together particulate materials to yield mortars, concretes and suchlike. The invention further provides construction materials formed by the methods of the invention, and bacterial strains which can be used in the methods of the invention to generate organic acids.

Abstract: Provided herein, in some aspects, are compositions and methods to inhibit AFP interactions with ?2M and/or Class I-related molecule interactions in diseases or disorders where elevated AFP levels are associated with immunosuppression. Also provided herein, in some aspects, are compositions and methods to enhance or potentiate AFP interactions with ?2M and/or Class I-related molecule in diseases or disorders with decreased AFP levels or diseases or disorders where increasing AFP levels is desired to increase immunosuppression or enhance organ regeneration.

Abstract: The present invention provides an inhibitor of an ADAMTS proteoglycanase for use in treating or preventing cardiac remodeling or for use in treating or preventing heart failure in a subject. In particular, the present invention provides an inhibitor of ADAMTS4 or ADAMTS5 for use in treating or preventing cardiac remodeling or chronic heart failure in a subject with cardiac remodeling or with chronic heart failure, or with a condition that may lead to cardiac remodeling and/or chronic heart failure. Also provided is a method of treating or preventing cardiac remodeling or treating or preventing heart failure which method comprises administering to a subject in need thereof a therapeutically effective amount of an inhibitor of an ADAMTS proteoglycanase. Also provided is the use of an inhibitor of an ADAMTS proteoglycanase in the manufacture of a medicament for treating or preventing cardiac remodeling or treating or preventing heart failure.

Abstract: The disclosure relates to outer membrane vesicles from Francisella and Piscirickettsia, and their use in vaccine compositions. In particular, the present disclosure relates to compositions and methods useful in inducing protective immunity against francisellosis or salmon rickettsial septicaemia (SRS) in fish.

Abstract: The present invention relates to methods and biomarkers (e.g., gene expression biomarkers) for detection of colorectal cancer in biological samples (e.g., tissue samples, biopsy samples, stool samples, blood samples, plasma samples, serum samples). In some embodiments, methods and biomarkers of the present invention find use in detection of colon cancer and in providing a prognosis to colorectal cancer patients.

Abstract: The present invention provides methods of determining a survival predictor score of a subject having mantle cell lymphoma (MCL). The present invention also provides methods of predicting the survival outcome of a subject having MCL and provides methods of selecting a treatment for a subject having MCL.

Abstract: The present invention relates to compositions and methods for antibody-mediated therapy. In particular, provided herein are engineered immunoglobulins with altered half-life.

Abstract: Compounds according to formula I are provided: A-L-B wherein A represents a lipophilic chelating moiety which is selective for Zn2+ ions; L is a covalent bond or a linker; and B is a vector which is either a moiety capable of interacting with one or more biological structures found in a bacterium (preferably in a bacterial cell wall), for example a penicillin-binding protein such as a metallo-?-lactamase or DD-transferase, or a moiety capable of enhancing transport of the compound across a bacterial cell membrane. A method of treating and/or preventing a bacterial infection in a human or non-human mammal employing such compounds are also provided. In such a method, the compound of formula I may be administered in combination with (either simultaneously, separately, or sequentially) a ?-lactam antibiotic.

Abstract: The present invention relates to albumin variants with an improved affinity for the neonatal Fc receptor (FcRn) and uses thereof, and in particular to the use of such albumin variants as carriers for immunogens. In some embodiments, the present invention relates to vaccines (e.g., vaccines for mucosal delivery) comprising albumin/immunogen fusion proteins.

Abstract: Provided herein are photosensitizer compounds for use in a variety of clinical, industrial, and research applications. In particular, provided are deep eutectic solvents and natural deep eutectic solvents for use in killing of bacteria.

Abstract: A patient isolator includes a base and a cover which is arranged to seal with the base. The cover is formed from a rigid material and has two access ports on an end face. The two access ports are angled in a width direction relative to a plane which extends parallel to the width direction of the patient isolator. The two access ports are angled relative to each other. A method of isolating a patient from an environment is also disclosed.

Abstract: Provided herein is technology relating to tomato extracts and particularly, but not exclusively to preparing and using tomato extracts as an anti-hypertensive agent to modulate blood pressure.

Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.

Abstract: The present invention relates to methods and kits for the detection of 5-hydroxymethylcytosine (5hmC) and/or 5-methylcytosine (5meC). In some embodiments, the present invention relates to methods and kits for detection of 5hmC and/or 5meC in nucleic acid (e.g., DNA, RNA). In some embodiments, the present invention relates to detection of 5hmC in genomic DNA, e.g., mammalian genomic DNA.

Abstract: A chest compression device for cardiopulmonary resuscitation may include a support structure for placement about a patient's chest and for holding a chest compressor above a patient's sternum; a chest compressor mounted on the support structure; and lateral chest supports attached to the support structure at points laterally on either side of the chest when the device is in use, such that the lateral chest supports will apply lateral pressure to the sides of the chest synchronised with a chest compression by the chest compressor.

Abstract: The disclosure relates to outer membrane vesicles from Francisella and Piscirickettsia, and their use in vaccine compositions. In particular, the present disclosure relates to compositions and methods useful in inducing protective immunity against francisellosis or salmon rickettsial septicaemia (SRS) in fish.

Abstract: The invention relates to cardio-protective agents. In particular, the present invention relates to cardio-protective extracts and fractions thereof prepared from kiwi fruit.

Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.

Abstract: A method for the formation of lithium includes a layer on a substrate using an atomic layer deposition method. The method includes the sequential pulsing of a lithium precursor through a reaction chamber for deposition upon a substrate. Using further oxidizing pulses and or other metal containing precursor pulses, an electrolyte suitable for use in thin film batteries may be manufactured.